RU2813943C1 - Method of treating benign parathyroid growths - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to endocrinology and surgery, and can be used for treating benign growths of the parathyroid gland. That is ensured by ultrasound-guided percutaneously injection into parathyroid adenoma area with 1 ml of 3% ethoxysclerol solution per 1 ml of parathyroid gland node volume. One month before the beginning of each course of sclerotherapy, alendronic acid is prescribed in tablets orally in dose of 70 mg once week for 28 days.

EFFECT: invention provides highly effective treatment of parathyroid adenoma.

1 cl, 1 ex

Description

The invention relates to medicine, namely to endocrinology and surgery, a method for treating parathyroid adenoma.

A number of agents are known for sclerotherapy of the thyroid and parathyroid glands - Ethoxysclerol was proposed for the treatment of benign tumors of the thyroid gland and Ethanol for sclerotherapy of the parathyroid gland [1,2,3].

However, we have not found any information on the use of Ethoxysklerol for the treatment of benign tumors of the parathyroid gland. Also, the above patents[1,2,3] do not indicate exactly how it is necessary to monitor the effectiveness of treatment with such agents and how to determine a sufficient period of treatment.

The task was set to create a highly effective scheme for sclerotherapy with Aethoxysclerol for a benign parathyroid tumor and evaluate the effectiveness of treatment.

The problem was solved by carrying out sclerotherapy, characterized in that 1 ml of a 3% solution of ethoxysclerol per 1 ml of the volume of the parathyroid gland node is injected percutaneously into the area of the parathyroid adenoma under ultrasound control, and a month before the start of each course of sclerotherapy, alendronic acid is prescribed for 28 days acid in tablets orally at a dose of 70 mg once a week.

The therapeutic effect of the proposed drug and method of application has been tested. No complications or side effects were identified when using this drug and the method of monitoring treatment. The effectiveness of use is explained by the medicinal value of the drug and the new proposed means of controlling the duration of treatment, which also eliminates relapses after the end of treatment.

An example of a specific implementation.

Example 1. Patient Z., 77 years old. Diagnosis: Primary hyperparathyroidism. Adenoma of the left inferior parathyroid gland. Before starting treatment, the following were performed: dynamically determined levels of parathyroid hormone, levels of albumin, phosphorus, calcium and ionized calcium, ultrasound of the parathyroid gland and thyroid gland, scintirraphy of the parathyroid gland. An adenoma of the left lower parathyroid gland measuring 18*17*15mm was discovered. The patient refused standard surgical treatment. Preparation was performed with Alendronic acid tablets orally at a dose of 70 mg once a week for a month. Then, under ultrasound control, 2.5 ml of a 3% solution of Aethoxysclerel was injected percutaneously into the area of the adenoma of the left lower parathyroid gland (around the adenoma and into the adenoma). There were no complications after the introduction of Aethoxysclerosis. 90 days after sclerotherapy, levels of parathyroid hormone, levels of albumin, phosphorus, calcium and ionized calcium were determined. Since 90 days after sclerotherapy, normalization of the levels of parathyroid hormone, ionized and total calcium was noted, there was no need for a second course of sclerotherapy.

The data obtained in the clinic allow us to recommend the developed method of sclerotherapy for parathyroid adenoma as a highly effective treatment for benign neoplasms of the parathyroid gland in people over 65 years of age, which has a pronounced clinical effect and has wide functionality for practical medicine.

Literature

Slashchuk K. Yu. Technologies of functional-topic visualization in the complex diagnosis of hyperparathyroidism. Dissertation for the degree of Candidate of Medical Sciences. Moscow - 2021. From 1-115.

Ivanova Olga Ivanovna (RU), Koveshnikova Marina Sergeevna (RU), Solomatina Tatyana Vasilievna (RU) RU 2003135006. 2003. Method of treatment of benign neoplasms of the thyroid gland.

Ivanova Olga Ivanovna (RU), Solomina Marina Sergeevna (RU) RU 2005115770. 2005. Method and means for the treatment of benign neoplasms of the thyroid gland.

Cao X., Cheng Z., Yu X. et al. Ultrasound-Guided Percutaneous Microwave Ablation of Parathyroid Adenoma. Journal of Vascular and Interventional Radiology. 2016; 27(12), 1929193.

Kitaoka M. et al. Ultrasonographic diagnosis of parathyroid glands and percutaneous ethanol injection therapy. Nephrol. Dial. Transplant. 2003; 18 (3): 27-30.

Claims (1)

A method for the treatment of benign neoplasms of the parathyroid gland, including sclerotherapy, characterized in that 1 ml of a 3% solution of ethoxysklerol per 1 ml of the volume of the parathyroid gland node is injected percutaneously into the area of the parathyroid adenoma under ultrasound control, one month before the start of each course of sclerotherapy for 28 days, alendronic acid is prescribed in tablets orally at a dose of 70 mg once a week.